Acute pharmacological effects of α-PVP in humans: a naturalistic observational study.
Georgina de la Rosa, Esther Papaseit, Olga Hladun, Lourdes Poyatos, Dolly Andrea Caicedo, Martha Catalina Argote, Soraya Martín, Mireia Ventura, Nunzia La Maida, Annagiulia Di Trana, Silvia Graziano, Simona Pichini, Magí Farré, Clara Pérez‐mañá
Frontiers in Pharmacology 2025 DOI: 10.3389/fphar.2025.1626692 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Non-controlled observational study Peer reviewed |
|---|---|
| Sample size | 9 |
| Population | Participants with a previous history of psychostimulant use |
| Intervention | α-PVP |
| Dose | 10 mg or 20 mg |
| Duration | 5 hours post-administration |
| Keywords | Cathinones New psychoactive substances Alpha-pyrrolidinopentiophenone α-pvp α-pvp Synthetic cathinone Pharmacology acute pharmacology Drug effects Physiological effects Psychostimulant effects Empathogenic properties Rapid onset Duration of action Psychostimulants stimulant effects Psychostimulant properties Cocaine-like effects Novel psychoactive substances Designer drugs |
| Citations | 7 |
| Key findings | Intranasal α-PVP produces rapid-onset psychostimulant and empathogenic effects similar to cocaine and MDMA, with acute cardiovascular changes peaking 40 minutes after administration and subjective effects lasting 3 to 5 hours. |
Abstract
Alpha-pyrrolidinopentiophenone (α-PVP) is a commonly consumed analogue of pyrovalerone, a synthetic cathinone with psychostimulant properties similar to those of 3,4-Methylenedioxypyrovalerone (MDPV) and cocaine. Since the pharmacology of α-PVP remains scarcely studied, we aimed to evaluate the acute pharmacological effects and its abuse potential in humans after intranasal administration. We carried out a non-controlled observational study in a naturalistic environment in nine participants (3 women and six men) with a previous history of psychostimulant use. Participants self-administered a single intranasal dose of 10mg or 20mg of α-PVP. The outcomes included physiological effects (systolic and diastolic blood pressure, heart rate, and temperature) and subjective effects (Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire_VESSPA-SSE, the short form of the Addiction Research Center Inventory questionnaire_ARCI and visual analog scales_VASs) and were measured at different time points (0, 20 and 40 minutes and 1, 1.5, 2, 2.5, 3, 4 and 5 hours). An acute increase in blood pressure and heart rate was observed that peaked 40 minutes after administration. Subjective effects also showed a rapid onset and disappeared 3 to 5 hours after administration. α-PVP showed psychostimulant properties similar to those displayed by cocaine and empathogenic effects commonly associated with MDMA and other cathinones (eg. methylone) consumption.
Citations in the library
Cited by 2
- Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use Molecular Psychiatry April 8, 2026
- How can we facilitate research on the risks and potential benefits of novel psychoactive substances? EClinicalMedicine June 19, 2026
Cites 16
- Pill content, dose and resulting plasma concentrations of 3,4‐methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users Addiction February 14, 2011
- Acute Pharmacological Effects of 2C-B in Humans: An Observational Study Frontiers in Pharmacology March 13, 2018
- Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicology in Vitro December 1, 2017
- Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition Clinical Pharmacology & Therapeutics May 30, 2023
- Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans Pharmaceuticals January 28, 2021
and 11 more in the library